Question.5464 - Imagine X5RL, a pharmaceutical company, develops a groundbreaking, patented treatment for a widespread chronic disease. X5RL sets a high price on the treatment to recover its R&D costs, fund future innovations, and reap profits. However, many patients – especially in low-income regions -- cannot afford the treatment due to lack of – or insufficient - insurance coverage. As a result, a significant measure of the population is foreclosed from the lifesaving treatment. • Is the public's financial issue X5RL's problem? Should it be? • How can this company integrate CSR principles into its strategy to profit from its IP and also provide equitable access, and what ethical considerations should guide this approach? • (HINT: Compare GSK and insulin producers in developing your thoughts). • In your peer replies, please do not simply find a post to “agree with.” Engage in respectful debate and develop an engaged discussion.
Answer Below:
The dilemma that X5RL faces highlights the ongoing tension between healthcare innovation that is motivated by business and social duty. On the one han...
The xxxxxxx that x RL xxxxx highlights xxx ongoing xxxxxxx between xxxxxxxxxx innovation xxxx is xxxxxxxxx by xxxxxxxx and xxxxxx duty xx the xxx hand xxx company's xxxx prices xxxx sense xxxx a xxxxxxxx point xx view xxxxxxxxxx new xxxxx is xxxx expensive xxx intellectual xxxxxxxx rights xxxx companies xxx their xxxxx back xxxxx also xxxxxxx discoveries xxxxx However xxx social xxxxxx can't xx ignored xxxx a xxx of xxxxxx especially xxxxx living xx low-income xxxxx can't xxx the xxxx that xxxxx save xxxxx lives xxxxxxxx not xxxxxx enough xxxxx might xxx be x RL's xxxxxxx in x legal xxxxx but xxx company xxxxxx care xxxxx this xxxxx because xx is xxx right xxxxx to xx GlaxoSmithKline xxx and xxxxx pharmaceutical xxxxxxxxx have xxxxx with xxxx tension xx using xxxxxx price xxxxxx giving xxxxxxxx for xxxxx to xxxxxxx makers xx developing xxxxxxxxx and xxxxxxx up xxxx global xxxxxx organizations x nder xx al xx the xxxxx hand xxxxxxx makers xxxx been xxxxxxxxxx for xxxxxxx prices xxxx even xx markets xxxxx money xx tight xxxxx has xxx to xxxxxx that xxxxx have xxxx avoided xxx charges xx greed x RL xxxxxx ethically xxxxxxxxxxx corporate xxxxxx responsibility xxxxxxxxxx by xxxxxxxxx profit xxxx access x hm xx al x believe xxxx could xx achieved xx partnering xxxx NGOs xx subsidize xxxxxxxxx in xxxxxxxxxx regions xxxxxxxx differential xxxxxxx strategies xx offering xxxxxxx assistance xxxxxxxx This xxxxxxxx not xxxx keeps xxx image xxxx and xxxxxx the xxxx of xxxxxxxxxxxx action xxx it xxxx shows x dedication xx sustainability xxx people's xxxxxxxxxx In xxxxxx words xxxxxxxxxx intellectual xxxxxxxx shouldn't xxxx companies xxxx doing xxxx Businesses xxxx combine xxxxxx money xxxx doing xxxx tend xx build xxxxx and xxxxxxxx in xxx market xxxx time xxxxxxxxxxx hm x Carrington x Cornelius x de xxxxx B xxxxxxxxx M xxxxxx L xxxx D xxxxxx at xxx centre xx global xxx local xxxxxxxxxx Thoughts xx the xxxxxx of xxxxxxxx ethics xxxxxxx of xxxxxxxx Ethics x B xxxx T xxxxxxx N xxxx J xxxxxxxxxx the xxxxxxxxxxx of xxxxxx Objectives xxxx Time x Case-Based xxxxxxxx of xxxxxx to xxxxxxxx in xxx Pharmaceutical xxxxxxxx Business xxxxxxx - xxxxx P xxxxxxx AND xxxx PRICING xxxxxxx MANAGEMENT xxxxxxxxxx TO xxxxxxxx MARKET xxxxxx
.ico)
.ico)
.ico)
